India Today on MSN

India sees alarming surge in fatty liver disease, ranks among global top 3

Once blamed on alcohol, the silent liver disease now tracks obesity, diabetes and modern lifestyles—and India is racing up ...

Lean fatty liver danger: Thin outside, but fat inside

The younger, seemingly fit population is increasingly being afflicted with lean fatty liver disease due to hidden visceral ...
Health and Me on MSN

India ranks third in non alcoholic fatty liver disease cases, study finds

Between 2010 and 2021, India recorded a 13.2 percent increase in non-alcoholic fatty liver disease (NAFLD) cases. According ...
Seeking Alpha

Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress

Late-breaking AI-based analysis of MAESTRO-NASH biopsy data demonstrates Rezdiffra improved key fibrotic features that are predictive of progression to decompensated cirrhosis Noninvasive test data ...
EurekAlert!

Multimodal learning-based prediction for nonalcoholic fatty liver disease

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease, and if it is accurately predicted ...
WTEN

Vrije Universiteit Brussel (VUB) and InSphero Partner to Advance Drug Discovery for Non-Alcoholic Steatohepatitis

InSphero, leader in enabling pharma researchers to use predictive, human 3D cell-based disease models expands its NASH portfolio in collaboration with VUB This licensing agreement allows us to bring ...
UUHC Health Feed

Liver Disease

Liver disease includes any condition that damages your liver. Over time, scar tissue can build up in your liver. Scarring or fibrosis can progress over many years until you develop cirrhosis—the most ...
Business Wire

HighTide Therapeutics’ HTD1801 Demonstrates Reduced Liver Fat, Improved Glycemic Control and Other Health Measures in Diabetic NASH Patients

SHENZHEN, China & ROCKVILLE, Md.--(BUSINESS WIRE)--Phase 2 clinical results with HTD1801, a novel orally active ionic salt of berberine and ursodeoxycholic acid, substantially reduced liver fat while ...
KTLA

Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023

NORCROSS, Ga., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will ...